FDA Ratchets Up Overseas Inspections For FY 2010 - 924 For Drug Activities
FDA expects to increase its oversight of overseas pharmaceutical company activities by one-third in fiscal 2010 as it doubles the total number of foreign inspections it conducts
You may also be interested in...
High-Risk Drug Imports To Be Delayed, FDA PREDICTs; Focus On Data Quality Can Avoid New 20 Percent Dragnet
An FDA information technology system designed to identify high-risk imports for possible inspection should speed U.S. entry for about 80 percent of FDA-regulated products coming into the country
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials